Monashee Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Monashee Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,829	Closed	-$25.6K	–	69
2024 Q3	$25.6K	Buy	+8,829	New	+$110K	﹤0.01%	109
2024 Q1	–	Sell	-8,829	Closed	-$34.9K	–	113
2023 Q4	$34.9K	Buy	+8,829	New	+$119K	0.01%	44
2023 Q1	–	Sell	-32,113	Closed	-$1.64M	–	65
2022 Q4	$1.64M	Buy	+32,113	New	+$2.23M	0.7%	34

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Monashee Investment Management's KPTI Position: Q4 2024 in Review

Monashee Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 8,829 shares — an estimated $25.6K sold.

Monashee Investment Management first reported a position in KPTI in Q4 2022 and held it in 3 quarters. The position peaked at $1.64M in Q4 2022. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

Monashee Investment Management reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
Monashee Investment Management sold 8,829 Karyopharm Therapeutics shares in Q4 2024, an estimated $25.6K.
Monashee Investment Management first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 3 quarters.
Monashee Investment Management's Karyopharm Therapeutics position peaked at $1.64M in Q4 2022.
87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Monashee Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.